Roundtable Lunch

Time: 12:40 pm
day: Day One

Details:

• Do you use humanized/HuGEMM mice to investigate other aspects of your therapeutic besides efficacy?
• At what stage of the drug development workflow should we start to
investigate any potential irAE toxicity of immunotherapies?
• What are your thoughts on using humanized/HuGEMM mice to investigate irAE?
• What are some of the models used to investigate immunotoxicity?

Speakers: